Androgens stimulate the growth of prostate cancer (PCa), and treatments such as chemical or surgical castration and antiandrogens, which prevent androgens from binding to the androgen receptor (AR), are employed to manage the disease.[3] This approach, known as androgen deprivation therapy (ADT), is effective in suppressing prostate cancer progression. This evidence concerns the gene AR and posterior cortical atrophy.